Projects

Randomized trial of focal prostate brachytherapy:

developed by UROGEC. The chief investigator is Bradley Pieters with funding from the Dutch Cancer Society. The trial design is a prospective two-arm open randomized trial comparing hemigland and whole gland prostate brachytherapy using either LDR or HDR with the primary endpoint of erectile function. The accrual target is s total of 254 patients. https://trialsearch.who.int/Trial2.aspx?TrialID=NTR727

LDR BT TURP study:

was a prospective study to evaluate urinary function in patients undergoing LDR brachytherapy for prostate cancer who had undergone a previous TURP which has been completed and is now being prepared for publication.

Salvage brachytherapy:

is increasingly being offered across Europe. UROGEC plan a prospective database to collect a large multicentre series of patients to provide robust data on efficacy and aid guidelines for patient selection.

Urinary toxicity:

is relatively common and current guidelines focus on urethral constraints as a planning objective to minimize urinary toxicity. We are seeking to explore other constraints which may have more relevance to bladder function for example trigone dose to help define new tolerance doses for these regions.